Stock Analysis
Shanghai Fosun Pharmaceutical (Group) First Quarter 2024 Earnings: Misses Expectations
Shanghai Fosun Pharmaceutical (Group) (SHSE:600196) First Quarter 2024 Results
Key Financial Results
- Revenue: CN¥10.2b (down 6.6% from 1Q 2023).
- Net income: CN¥609.7m (down 38% from 1Q 2023).
- Profit margin: 6.0% (down from 9.1% in 1Q 2023). The decrease in margin was driven by lower revenue.
- EPS: CN¥0.23 (down from CN¥0.37 in 1Q 2023).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Shanghai Fosun Pharmaceutical (Group) Revenues and Earnings Miss Expectations
Revenue missed analyst estimates by 5.0%. Earnings per share (EPS) also missed analyst estimates by 15%.
Looking ahead, revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 14% growth forecast for the Pharmaceuticals industry in China.
Performance of the Chinese Pharmaceuticals industry.
The company's shares are up 4.0% from a week ago.
Risk Analysis
You should always think about risks. Case in point, we've spotted 2 warning signs for Shanghai Fosun Pharmaceutical (Group) you should be aware of.
Valuation is complex, but we're helping make it simple.
Find out whether Shanghai Fosun Pharmaceutical (Group) is potentially over or undervalued by checking out our comprehensive analysis, which includes fair value estimates, risks and warnings, dividends, insider transactions and financial health.
View the Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About SHSE:600196
Shanghai Fosun Pharmaceutical (Group)
Shanghai Fosun Pharmaceutical (Group) Co., Ltd.
Excellent balance sheet with moderate growth potential.